Week in Review: Cannabis & Psychedelics Industry Highlights

LOS ANGELES – Big Pharma stopped dipping its toe and dove in headfirst. A $3.8 billion psychedelic acquisition closed. A hostile Cannabis takeover escalated into a full public war of facts and figures, with a December deadline for shareholders to decide. Operators pushed into new states, capital markets moved, and regulators in Virginia, New York, and the Netherlands took steps that will shape retail for years. The past fortnight has built up its own momentum, bringing the capital, science and deals together in all the right ways.

1. Aurora vs. Curaleaf Goes from Dispute to All-Out War

If one Cannabis development dominated the two weeks, it was the Aurora-Curaleaf fight, and it got louder, more specific, and more far-reaching than it was before.

Curaleaf issued a 14-point public fact sheet taking direct aim at what it described as misleading statements Aurora has circulated in opposition to its hostile bid, which values Aurora at approximately US$272 million. Curaleaf’s response was pointed. On Aurora’s debt criticism, the company’s most repeated line of attack, Curaleaf’s position was direct: debt can be repaid, dilution is permanent.

Aurora and Curaleaf then traded further public statements, each sharpening its narrative for shareholders. Aurora’s board unanimously rejected the proposal and urged shareholders to take no action.

Curaleaf escalated further by asking Alberta’s securities regulator to freeze Aurora’s share sales, a procedural move designed to limit Aurora’s ability to raise additional capital via dilutive At-the-Market issuances during the live offer period. It is an aggressive tactic – one that shifts the fight from press releases to regulatory filings and signals that Curaleaf intends to make Aurora’s preferred financing method a liability.

Separately, Aurora reaffirmed its growth outlook on the strength of its European operations, pointing to its international medical Cannabis business as evidence that its standalone value exceeds what Curaleaf’s bid implies. The European card is central to Aurora’s defense. It is the asset that least overlaps with Curaleaf’s U.S.-heavy footprint, and therefore the hardest for Curaleaf to credibly price from the outside.

Aurora has until December 1 to produce a credible counter: a competing offer, a standalone performance plan backed by hard milestones, or an actual seat at the negotiating table.

2. Operators Expand, Consolidate & Settle Debt

The M&A calendar stayed busy. Grown Rogue launched cultivation operations in Minnesota, planting its flag in a newly legal adult-use state and extending its multistate footprint further east.

The PharmaCann saga took a harder turn. Opus Consulting was appointed receiver for PharmaCann’s Maryland assets, a development that reflects the financial strain that has followed the company’s protracted acquisition discussions.

TerrAscend closed its acquisition of Aunt Mary’s dispensary in New Jersey, adding a retail foothold in one of the East Coast’s most competitive legal markets.

Medical Saints moved to acquire Christina Lake Cannabis in an $18 million deal, targeting a cultivator with established Canadian and international supply relationships.

On the capital side, Cannara Biotech secured an upgraded $80 million credit line, giving the Cannabis company the financial runway to fund operations and expansion without tapping equity markets at unfavorable terms.

Vireo Growth settled the Altmore claim through share issuance, resolving a legal dispute by converting a liability into equity – a structure that preserves cash but outlines ongoing constraints on liquidity.

High Tide reported its Q3 2026 financial results, adding to a quarter in which Canadian operators broadly demonstrated tighter cost management and more deliberate capital allocation than in previous cycles.

3. Policy & Market Development Keep Pace

Virginia unveiled its draft rules for an adult-use Cannabis market, one of the most-watched regulatory developments of the cycle. Virginia’s proposed framework will shape licensing, taxation, and social equity provisions for a state with significant market potential on the East Coast.

In New York, compliance infrastructure took a step forward. Metrc rolled out compliance events for New York Cannabis operators, giving licensed businesses a structured mechanism for tracking inventory and reporting obligations in a market that has been grinding through implementation challenges since adult use launched.

North Carolina’s path to legalization got a clearer public mandate. Survey data shows strengthening support for Cannabis in North Carolina, with majorities backing adult-use legalization across party lines.

4. International Markets Move Forward

The Netherlands produced the most notable international result of the cycle. The Dutch regulated Cannabis supply pilot reported lower prices and fuller shelves at participating retail locations – a direct rebuke to the long-standing argument that regulated supply cannot compete with the legacy market on price or variety. The pilot is being watched across Europe as a template for regulated adult-use retail at the national level.

Cannaflex opened a European export route, adding to a growing network of international Cannabis trade flows that increasingly connect North American and Southern Hemisphere producers to European medical markets.

5. The Biggest Pharma Bet Psychedelics Has Ever Seen

The defining transaction of the cycle was not a Cannabis deal. Eli Lilly completed acquisition of AtaiBeckley for approximately $2.8 billion in equity value – with contingent value rights bringing total potential consideration to $3.8 billion, closing after the premerger antitrust review period expired on August 28. The asset at the center of the deal is BPL-003, a proprietary intranasal formulation of 5-MeO-DMT holding FDA Breakthrough Therapy Designation that entered two simultaneous Phase 3 studies in Q2 2026. Phase 2b data across 193 patients showed statistically significant reductions in depression scores lasting up to eight weeks on a single dose, with most patients discharge-ready roughly 100 minutes after administration.

Definium Therapeutics achieved its second positive Phase 3 readout for its LSD-based candidate in generalized anxiety disorder, extending a streak of convincing efficacy data that now spans two major psychiatric indications. The company holds FDA Breakthrough Therapy Designation for GAD and has become one of the most closely watched names in psychedelic therapeutics.

At the earliest stage of the pipeline, Xylo Bio advanced its lead compound into a first-in-human clinical trial, moving a novel psychedelic-derived molecule from preclinical research into human subjects. First-in-human milestones rarely move markets on their own, but in a sector where every new entrant into clinical development expands the credibility of the category, the filing matters.

HCN & Its Network

Safe Harbor Equity and Highly Capitalized Network announced a strategic capital advisory and investor outreach partnership, pairing HCN’s industry reach with Safe Harbor’s Cannabis-specialized financial advisory capabilities. The collaboration targets capital formation, investor relations, and strategic positioning for operators navigating a market where access to institutional capital remains the defining competitive variable.

HCN Insight

Two developments defined this cycle, and they are not unrelated.

The first is Eli Lilly’s $3.8 billion close on AtaiBeckley. This is the third major pharma acquisition of a psychedelic-derived therapy platform in under twelve months, and it is the largest by total consideration. When companies the size of Lilly commit this kind of capital [not to exploration, not to minority stakes, but to full acquisitions with contingent milestones tied to clinical outcomes] the sector has cleared a threshold that cannot be walked back. The infrastructure question that follows is equally important: payers, regulators, and clinical systems are not ready for the volume of patients these drugs could serve. Building that infrastructure is the next decade’s work.

The second is Aurora vs Curaleaf. Strip away the press releases and what you have is a forced negotiation over what Canadian Cannabis is worth, and by extension, what cross-border consolidation looks like when one party controls the narrative and the other controls the clock. Curaleaf’s regulatory escalation in Alberta changes the dynamics of the standoff. Aurora’s European revenue case is genuine, but it needs to be translated into shareholder value by December 1. Demonstrated, not simply declared. The outcome of this fight will set the reference points for every cross-border Cannabis M&A conversation in 2027.

Taken together, these two developments point toward the same destination: an industry being priced, contested, negotiated, and restructured by institutional actors who are now playing for keeps. The window for operators and investors to position ahead of that consolidation is narrowing.